Clinical trial
AB122 Platform Study
NCT04999761
Study timeline
Study start (actual)2021-06-01Date precision: day
Registry last updated2026-08-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Advanced or Metastatic Solid Tumorunresolved
Pancreatic Ductal Adenocarcinomaunresolved
Colorectal Cancerunresolved
Non-small Cell Lung Cancerunresolved
Gastric Cancerunresolved
Alveolar Soft Part Sarcomaunresolved
Esophageal Cancerunresolved
Head and Neck Cancerunresolved
Biliary Tract Cancerunresolved
Interventions
AB122DRUG
AB122DRUG
TAS-116DRUG
TAS-120DRUG
TAS-115DRUG
TAS-102DRUG
RamucirumabDRUG
TAS-102DRUG
BevacizumabDRUG
FluorouracilDRUG
CisplatinDRUG
AB154DRUG
FluorouracilDRUG
CarboplatinDRUG
CisplatinDRUG
CarboplatinDRUG
nab-PaclitaxelDRUG
CisplatinDRUG
GemcitabineDRUG
nab-PaclitaxelDRUG
GemcitabineDRUG
Sponsors & collaborators
Taiho Pharmaceutical Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04999761 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.